What is the interaction between Omeprazole and Factor VIII (FVIII, Anti-hemophilic factor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Omeprazole does not have any significant interactions with Factor VIII therapy, and patients can safely take them together without dose adjustments. This is because omeprazole, a proton pump inhibitor, reduces stomach acid production, while Factor VIII is a clotting factor used to treat or prevent bleeding in people with hemophilia A, and they work through completely different mechanisms in the body without interfering with each other's effectiveness. The absorption, metabolism, and excretion pathways for these medications are distinct, which explains the lack of clinically significant interactions, as noted in various studies 1, 2, 3, 4, 5.

Key Points to Consider

  • For patients with hemophilia A who also have acid-related disorders like GERD or peptic ulcers, standard dosing of omeprazole (typically 20-40 mg daily) can be used alongside their prescribed Factor VIII replacement therapy without concerns about reduced efficacy or increased side effects.
  • It is essential for patients to inform all their healthcare providers about all medications they are taking to ensure comprehensive care.
  • The development of new treatments for hemophilia A, such as gene therapy and long-acting recombinant factor VIII products, offers promising alternatives but does not affect the interaction between omeprazole and Factor VIII therapy, as discussed in studies like 2 and 4.
  • The safety of switching factor VIII products has been evaluated, and while it is a consideration in the management of hemophilia A, it does not impact the use of omeprazole with Factor VIII, as seen in 5.

Clinical Implications

  • Clinicians should be aware that omeprazole and Factor VIII can be co-administered without dose adjustments, simplifying the management of patients with hemophilia A who require treatment for acid-related disorders.
  • The focus should remain on the individual patient's needs, including the management of hemophilia A and any comorbid conditions, such as GERD or peptic ulcers, with appropriate monitoring and adjustment of treatments as necessary, guided by the latest evidence 1, 2, 3, 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.